SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new drug combo outperform standard therapy for lung cancer?
Disease control Not yet recruitingThis phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a novel drug combo outperform chemo in lung cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New lung cancer cocktail aims to outperform current standard therapy
Disease control Not yet recruitingThis clinical trial compares a new three-drug combination (SYHX2011, carboplatin, and enlonstobart) against the standard three-drug regimen (nab-paclitaxel, carboplatin, and tislelizumab) as a first treatment for people with advanced squamous non-small cell lung cancer. The study…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New vaccine combo takes on tough lung cancer in early trial
Disease control Not yet recruitingThis early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo aims to outperform standard immunotherapy in lung cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether a new experimental drug called HB0025, combined with chemotherapy, works better than the standard immunotherapy pembrolizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer. About 480 participants who have not had p…
Matched conditions: SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC